O	0	1	A
O	2	12	Randomized
O	12	13	,
O	14	18	Open
O	18	19	-
O	19	24	Label
O	24	25	,
O	26	37	Multicenter
O	37	38	,
O	39	44	Phase
O	45	48	III
O	49	54	Study
O	55	57	of
B-intervention	58	65	Epoetin
I-intervention	66	70	Alfa
O	71	77	Versus
B-control	78	82	Best
I-control	83	91	Standard
I-control	92	94	of
I-control	95	99	Care
O	100	102	in
O	103	109	Anemic
O	110	118	Patients
O	119	123	With
O	124	134	Metastatic
O	135	141	Breast
O	142	148	Cancer
O	149	158	Receiving
O	159	167	Standard
O	168	180	Chemotherapy
O	180	181	.

O	182	184	An
O	185	189	open
O	189	190	-
O	190	195	label
O	195	196	,
O	197	211	noninferiority
O	212	217	study
O	218	220	to
O	221	229	evaluate
O	230	233	the
O	234	240	impact
O	241	243	of
O	244	251	epoetin
O	252	256	alfa
O	257	258	(
O	258	261	EPO
O	261	262	)
O	263	265	on
O	266	271	tumor
O	272	280	outcomes
O	281	285	when
O	286	290	used
O	291	293	to
O	294	299	treat
O	300	306	anemia
O	307	309	in
O	310	318	patients
O	319	328	receiving
O	329	341	chemotherapy
O	342	345	for
O	346	356	metastatic
O	357	363	breast
O	364	370	cancer
O	370	371	.

B-eligibility	372	377	Women
I-eligibility	378	382	with
I-eligibility	383	393	hemoglobin
I-eligibility	394	395	â‰¤
I-eligibility	396	398	11
I-eligibility	398	399	.
I-eligibility	399	400	0
I-eligibility	401	402	g
I-eligibility	402	403	/
I-eligibility	403	405	dL
I-eligibility	405	406	,
I-eligibility	407	416	receiving
I-eligibility	417	422	first
I-eligibility	422	423	-
I-eligibility	424	426	or
I-eligibility	427	433	second
I-eligibility	433	434	-
I-eligibility	434	438	line
I-eligibility	439	451	chemotherapy
I-eligibility	452	455	for
I-eligibility	456	466	metastatic
I-eligibility	467	473	breast
I-eligibility	474	480	cancer
O	480	481	,
O	482	486	were
O	487	495	randomly
O	496	504	assigned
O	505	507	to
O	508	511	EPO
O	512	514	40
O	514	515	,
O	515	518	000
O	519	521	IU
O	522	536	subcutaneously
O	537	541	once
O	542	543	a
O	544	548	week
O	549	551	or
O	552	556	best
O	557	565	standard
O	566	568	of
O	569	573	care
O	573	574	.

O	575	578	The
O	579	586	primary
O	587	590	end
O	591	596	point
O	597	600	was
B-outcome-Measure	601	612	progression
I-outcome-Measure	612	613	-
I-outcome-Measure	613	617	free
I-outcome-Measure	618	626	survival
I-outcome-Measure	627	628	(
I-outcome-Measure	628	631	PFS
I-outcome-Measure	631	632	)
O	632	633	.

O	634	643	Secondary
O	644	647	end
O	648	654	points
O	655	663	included
B-outcome-Measure	664	671	overall
I-outcome-Measure	672	680	survival
O	680	681	,
B-outcome-Measure	682	686	time
I-outcome-Measure	687	689	to
I-outcome-Measure	690	695	tumor
I-outcome-Measure	696	707	progression
O	707	708	,
B-outcome-Measure	709	716	overall
I-outcome-Measure	717	725	response
I-outcome-Measure	726	730	rate
O	730	731	,
B-outcome-Measure	732	735	RBC
I-outcome-Measure	736	748	transfusions
O	748	749	,
O	750	753	and
B-outcome-Measure	754	764	thrombotic
I-outcome-Measure	765	773	vascular
I-outcome-Measure	774	780	events
O	780	781	.

O	782	784	In
B-total-participants	785	786	2
I-total-participants	786	787	,
I-total-participants	787	790	098
O	791	799	patients
O	800	808	randomly
O	809	817	assigned
O	817	818	,
B-outcome	819	825	median
I-outcome	826	829	PFS
O	830	831	(
O	831	836	based
O	837	839	on
O	840	852	investigator
O	852	853	-
O	853	863	determined
O	864	871	disease
O	872	883	progression
O	884	885	[
O	885	887	PD
O	887	888	]
O	888	889	)
O	890	893	was
O	894	895	7
O	895	896	.
O	896	897	4
O	898	904	months
O	905	907	in
O	908	912	both
O	913	919	groups
O	920	921	(
O	921	927	hazard
O	928	933	ratio
O	934	935	[
O	935	937	HR
O	937	938	]
O	938	939	,
O	940	941	1
O	941	942	.
O	942	945	089
O	945	946	;
O	947	949	95
O	949	950	%
O	951	953	CI
O	953	954	,
O	955	956	0
O	956	957	.
O	957	960	988
O	961	963	to
O	964	965	1
O	965	966	.
O	966	969	200
O	969	970	)
O	970	971	;
O	972	977	upper
O	978	983	bound
O	984	992	exceeded
O	993	1005	prespecified
O	1006	1020	noninferiority
O	1021	1027	margin
O	1028	1030	of
O	1031	1032	1
O	1032	1033	.
O	1033	1035	15
O	1035	1036	.

B-outcome	1037	1043	Median
I-outcome	1044	1047	PFS
O	1048	1051	per
O	1052	1063	independent
O	1064	1070	review
O	1071	1080	committee
O	1080	1081	-
O	1081	1091	determined
O	1092	1094	PD
O	1095	1098	was
B-iv-cont-median	1099	1100	7
I-iv-cont-median	1100	1101	.
I-iv-cont-median	1101	1102	6
I-iv-cont-median	1103	1109	months
O	1110	1112	in
O	1113	1117	both
O	1118	1124	groups
O	1125	1126	(
O	1126	1128	HR
O	1128	1129	,
O	1130	1131	1
O	1131	1132	.
O	1132	1135	028
O	1135	1136	;
O	1137	1139	95
O	1139	1140	%
O	1141	1143	CI
O	1143	1144	,
O	1145	1146	0
O	1146	1147	.
O	1147	1150	922
O	1151	1153	to
O	1154	1155	1
O	1155	1156	.
O	1156	1159	146
O	1159	1160	)
O	1160	1161	;
O	1162	1167	upper
O	1168	1173	bound
O	1174	1177	did
O	1178	1181	not
O	1182	1188	exceed
O	1189	1201	prespecified
O	1202	1216	noninferiority
O	1217	1223	margin
O	1223	1224	.

B-outcome	1225	1231	Median
I-outcome	1232	1239	overall
I-outcome	1240	1248	survival
I-outcome	1249	1251	at
I-outcome	1252	1260	clinical
I-outcome	1261	1267	cutoff
O	1268	1269	(
O	1269	1270	1
O	1270	1271	,
O	1271	1274	337
O	1275	1281	deaths
O	1281	1282	)
O	1283	1286	was
B-iv-cont-median	1287	1289	17
I-iv-cont-median	1289	1290	.
I-iv-cont-median	1290	1291	2
I-iv-cont-median	1292	1298	months
O	1299	1301	in
O	1302	1305	the
O	1306	1309	EPO
O	1310	1313	and
B-cv-cont-median	1314	1316	17
I-cv-cont-median	1316	1317	.
I-cv-cont-median	1317	1318	4
I-cv-cont-median	1319	1325	months
O	1326	1328	in
O	1329	1332	the
O	1333	1337	best
O	1338	1346	standard
O	1347	1349	of
O	1350	1354	care
O	1355	1360	group
O	1361	1362	(
O	1362	1364	HR
O	1364	1365	,
O	1366	1367	1
O	1367	1368	.
O	1368	1371	057
O	1371	1372	;
O	1373	1375	95
O	1375	1376	%
O	1377	1379	CI
O	1379	1380	,
O	1381	1382	0
O	1382	1383	.
O	1383	1386	949
O	1387	1389	to
O	1390	1391	1
O	1391	1392	.
O	1392	1395	177
O	1395	1396	)
O	1396	1397	,
B-outcome	1398	1404	median
I-outcome	1405	1409	time
I-outcome	1410	1412	to
I-outcome	1413	1418	tumor
I-outcome	1419	1430	progression
O	1431	1434	was
B-iv-cont-median	1435	1436	7
I-iv-cont-median	1436	1437	.
I-iv-cont-median	1437	1438	5
I-iv-cont-median	1439	1445	months
O	1446	1448	in
O	1449	1453	both
O	1454	1460	groups
O	1461	1462	(
O	1462	1464	HR
O	1464	1465	,
O	1466	1467	1
O	1467	1468	.
O	1468	1471	094
O	1471	1472	;
O	1473	1475	95
O	1475	1476	%
O	1477	1479	CI
O	1479	1480	,
O	1481	1482	0
O	1482	1483	.
O	1483	1486	991
O	1487	1489	to
O	1490	1491	1
O	1491	1492	.
O	1492	1495	209
O	1495	1496	)
O	1496	1497	,
O	1498	1501	and
B-outcome	1502	1509	overall
I-outcome	1510	1518	response
I-outcome	1519	1523	rate
O	1524	1527	was
B-iv-bin-percent	1528	1530	50
I-iv-bin-percent	1530	1531	%
O	1532	1538	versus
B-cv-bin-percent	1539	1541	51
I-cv-bin-percent	1541	1542	%
O	1543	1544	(
O	1544	1548	odds
O	1549	1554	ratio
O	1554	1555	,
O	1556	1557	0
O	1557	1558	.
O	1558	1561	950
O	1561	1562	;
O	1563	1565	95
O	1565	1566	%
O	1567	1569	CI
O	1569	1570	,
O	1571	1572	0
O	1572	1573	.
O	1573	1576	799
O	1577	1579	to
O	1580	1581	1
O	1581	1582	.
O	1582	1585	130
O	1585	1586	)
O	1586	1587	.

B-outcome	1588	1591	RBC
I-outcome	1592	1604	transfusions
O	1605	1609	were
B-iv-bin-percent	1610	1611	5
I-iv-bin-percent	1611	1612	.
I-iv-bin-percent	1612	1613	8
I-iv-bin-percent	1613	1614	%
O	1615	1621	versus
B-cv-bin-percent	1622	1624	11
I-cv-bin-percent	1624	1625	.
I-cv-bin-percent	1625	1626	4
I-cv-bin-percent	1626	1627	%
O	1628	1629	(
O	1629	1630	P
O	1631	1632	<
O	1633	1634	.
O	1634	1637	001
O	1637	1638	)
O	1638	1639	,
O	1640	1643	and
B-outcome	1644	1654	thrombotic
I-outcome	1655	1663	vascular
I-outcome	1664	1670	events
O	1671	1675	were
B-iv-bin-percent	1676	1677	2
I-iv-bin-percent	1677	1678	.
I-iv-bin-percent	1678	1679	8
I-iv-bin-percent	1679	1680	%
O	1681	1687	versus
B-cv-bin-percent	1688	1689	1
I-cv-bin-percent	1689	1690	.
I-cv-bin-percent	1690	1691	4
I-cv-bin-percent	1691	1692	%
O	1693	1694	(
O	1694	1695	P
O	1696	1697	=
O	1698	1699	.
O	1699	1702	038
O	1702	1703	)
O	1703	1704	,
O	1705	1717	respectively
O	1717	1718	.

O	1719	1722	The
O	1723	1730	primary
O	1731	1734	end
O	1735	1740	point
O	1740	1741	,
O	1742	1745	PFS
O	1746	1751	based
O	1752	1754	on
O	1755	1767	investigator
O	1767	1768	-
O	1768	1778	determined
O	1779	1781	PD
O	1781	1782	,
O	1783	1786	did
O	1787	1790	not
O	1791	1795	meet
O	1796	1810	noninferiority
O	1811	1819	criteria
O	1819	1820	.

O	1821	1823	As
O	1824	1825	a
O	1826	1837	consistency
O	1838	1848	assessment
O	1849	1853	with
O	1854	1857	the
O	1858	1865	primary
O	1866	1873	finding
O	1873	1874	,
O	1875	1878	PFS
O	1879	1884	based
O	1885	1887	on
O	1888	1899	independent
O	1900	1906	review
O	1907	1916	committee
O	1916	1917	-
O	1917	1927	determined
O	1928	1930	PD
O	1931	1934	met
O	1935	1949	noninferiority
O	1950	1958	criteria
O	1958	1959	.

O	1960	1967	Overall
O	1967	1968	,
O	1969	1973	this
O	1974	1979	study
O	1980	1983	did
O	1984	1987	not
O	1988	1995	achieve
O	1996	2010	noninferiority
O	2011	2020	objective
O	2021	2023	in
O	2024	2030	ruling
O	2031	2034	out
O	2035	2036	a
O	2037	2039	15
O	2039	2040	%
O	2041	2050	increased
O	2051	2055	risk
O	2056	2058	in
O	2059	2061	PD
O	2061	2062	/
O	2062	2067	death
O	2067	2068	.

O	2069	2072	RBC
O	2073	2084	transfusion
O	2085	2091	should
O	2092	2094	be
O	2095	2098	the
O	2099	2108	preferred
O	2109	2117	approach
O	2118	2121	for
O	2122	2125	the
O	2126	2136	management
O	2137	2139	of
O	2140	2146	anemia
O	2147	2149	in
O	2150	2154	this
O	2155	2165	population
O	2165	2166	.
